Virabiotics

Virabiotics is a pre-clinical stage biotechnology company specializing in the development of 'nanodecoy' therapeutics for viral infections. The company's proprietary ViraBlock platform involves coating synthetic nanoparticle cores with natural cell membranes derived from host cells that viruses naturally target. These decoys present the same receptors as real cells, tricking viruses into binding to the nanoparticles instead of infecting the patient's lungs or other organs. This approach is designed to be 'mutation-proof' because it targets the virus's fundamental need to bind to specific host receptors. Virabiotics is initially focusing on respiratory viruses, including SARS-CoV-2 and various strains of influenza, with the goal of providing a broad-spectrum solution that can be rapidly adapted to emerging viral threats.